Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 12Phase 1/2 5Phase 1 5Phase 2/3 4Phase NA 2Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Medulloblastoma 1Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 7Radiotherapy 6Bevacizumab 5Magnetic Resonance Spectroscopy 3ribociclib 2olaparib 2fluorodopa F 18 2fluciclovine F-18 2atezolizumab 2abemaciclib 2Surgical Procedures, Operative 2Specimen Handling 2Radiation 2Ketoconazole 2Everolimus 2Disulfiram 2Carvedilol 2zimberelimab 1tinostamustine 1temsirolimus 1senicapoc 1sacituzumab govitecan 1posaconazole 1pitavastatin 1perampanel 1pamiparib 1palbociclib 1niraparib 1mycophenolic adenine dinucleotide 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Glioblastoma × Lomustine × Clear all
NCT05017610 2022-12-02

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Emory University

Phase EARLY_PHASE1 Withdrawn
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡